ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Strengthening DNA to Prevent Inflammation, Heart Disease, Dementia and More

Magnesium: Widespread Deficiency with Deadly Consequences

Turmeric compound boosts regeneration of brain stem cells

CoQ10: The Longevity Factor

Culprits of Autism Identified: Toxins, Gut Bacteria, Nutritional Deficiencies, and Vaccines Made wit...

Omega-3 Fatty Acids Increase Brain Volume

Optimal Prostate Defense Requires a Multi-Modal Strategy

Use of Broad-Spectrum Antibiotics Before Age 2 Associated with Obesity Risk

Extending Life and Fighting Disease with Resveratrol

How Lipoic Acid Preserves Critical Mitochondrial Function

 
Print Page
Email Article

Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database – Source: British Medical Journal, May 20, 2010

  [ 61 votes ]   [ 1 Comment ]
By John Hippisley-Cox, Carol Coupland • www.ProHealth.com • May 23, 2010


[Note: To read the full text of this article and tables free online, click here]

Objective: To quantify the unintended effects of statins according to type, dose, and duration of use.

Design: Prospective open cohort study using routinely collected data.

Setting: 368 general practices in England and Wales supplying data to the QResearch database.

Participants: 2,004,692 patients aged 30-84 years of whom 225,922 (10.7%) were new users of statins: 159,790 (70.7%) were prescribed simvastatin, 50,328 (22.3%) atorvastatin, 8,103 (3.6%) pravastatin, 4,497 (1.9%) rosuvastatin, and 3,204 (1.4%) fluvastatin.

Methods: Cox proportional hazards models were used to estimate effects of statin type, dose, and duration of use. The number needed to treat (NNT) or number needed to harm (NNH) was calculated and numbers of additional or fewer cases estimated for 10,000 treated patients.

Main Outcome Measure:
First recorded occurrence of cardiovascular disease, moderate or serious myopathic events [muscle pain/weakness], moderate or serious liver dysfunction, acute renal [kidney] failure, venous thromboembolism, Parkinson's disease, dementia, rheumatoid arthritis, cataract, osteoporotic fracture, gastric cancer, esophageal cancer, colon cancer, lung cancer, melanoma, renal cancer, breast cancer, or prostate cancer.

Results:

• Individual statins were not significantly associated with risk of Parkinson's disease, rheumatoid arthritis, venous thromboembolism, dementia, osteoporotic fracture, gastric cancer, colon cancer, lung cancer, melanoma, renal cancer, breast cancer, or prostate cancer.

• Statin use was associated with decreased risks of esophageal cancer

• But increased risks of:
- Moderate or serious liver dysfunction,
- Acute renal failure,
- Moderate or serious myopathy [muscle disease],
- And cataract.

• Adverse effects were similar across statin types for each outcome except liver dysfunction where risks were highest for fluvastatin.

• A dose-response effect [higher dose, increased effect] was apparent for acute renal failure and liver dysfunction.

• All increased risks persisted during treatment and were highest in the first year.

• After stopping treatment:
- The risk of cataract returned to normal within a year in men and women.
- Risk of oesophageal cancer returned to normal within a year in women and within 1-3 years in men.
- Risk of acute renal failure returned to normal within 1-3 years in men and women,
- And liver dysfunction within 1-3 years in women and from three years in men.

• Based on the 20% threshold for cardiovascular risk, for women the NNT (number needed to treat) with any statin to prevent one case of cardiovascular disease over five years was 37 (95% confidence interval 27 to 64) and for esophageal cancer was 1,266 (850 to 3,460) and for men the respective values were 33 (24 to 57) and 1,082 (711 to 2,807).

• In women the NNH (number needed to harm) for an additional case of acute renal failure over five years was 434 (284 to 783), of moderate or severe myopathy was 259 (186 to 375), of moderate or severe liver dysfunction was 136 (109 to 175), and of cataract was 33 (28 to 38). Overall, the NNHs and NNTs for men were similar to those for women, except for myopathy where the NNH was 91 (74 to 112).

Conclusions:

• Claims of unintended benefits of statins, except for esophageal cancer, remain unsubstantiated,

• Although potential adverse effects at population level were confirmed and quantified.

Further studies are needed to develop utilities to individualize the risks so that patients at highest risk of adverse events can be monitored closely.

Source: British Medical Journal, May 20, 2010. PMID: 20488911, by Hippisley-Cox J, Coupland C. Division of Primary Care, University Park, Nottingham, UK. [Email: julia.hippisley-cox@ntlworld.com]




Please Discuss This Article:   Post a Comment 

Statins and ME/CFIDS
Posted by: CWB
Jun 2, 2010
I'm glad that additional studies on the effects of statins are being done, and think there should be more. As I've commented before on this website, I descended into severe ME/CFIDS after being put on statins when my cholesterol had skyrocketed by 100 points in six months despite execellent diet and exercise. I learend in other research that it is not uncommon for this to happen with this illness before major relapse, and that the theory is that the body is producing more cholesterol needed for healthy cell membranes to inhibit viral replication and improve cellular metabolism. I also question if the standard liver function tests are enough, that maybe endocrine function should also be measured because the liver doesn't just metabolize lipids/fats, it also fights pathogens and creates most of our hormones. I had the double injury of being put on birth control pills at the same time to manage other health conditions, but on reflection I see that my poor liver could not handle all of those tasks at once. In subsequent cholesterol research, I've learned that tests on statins have been more common with men (aimed at how heart disease jpresents in them), and not in women, which could be a big factor in this lack of vital info about side effects. My aim here is to help my fellow patients have information and questions I wish I'd had before being knocked out of the working world and into disability.
Reply Reply
 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid

Natural Remedies

Itching to Find Dry Skin Relief? Itching to Find Dry Skin Relief?
Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH
The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
Research Links Green Tea to Weight Loss Research Links Green Tea to Weight Loss

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing